Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 7 recruiting clinical trials
Advanced or metastatic NSCLC with EGFR gene mutations
PALOMA-2
Phase
NCT05498428
Compound
Amivantamab (EGFR × MET bispecific Ab) ± lazertinib (3rd generation EGFR TKI) or carboplatin + pemetrexed
Metastatic NSCLC
KaRAnaSa
Phase
NCT07227025
Compound
Amivantamab (EGFR × MET bispecific Ab) + olomorasib
Advanced or metastatic NSCLC with EGFR gene mutations
COPERNICUS
Phase
b
NCT06667076
Compound
Amivantamab (EGFR × MET bispecific Ab) ± lazertinib (3rd generation EGFR TKI) or CT
Resectable EGFRm NSCLC
AmiNA*
Phase
NCT07586202
Compound
Amivantamab (EGFR × MET bispecific Ab) ± lazertinib (3rd generation EGFR TKI) or CT
Locally advanced and unresectable Stage 3 NSCLC
CONVERGE
Phase
NCT06667908
Compound
JNJ-90301900 (NBTXR3) + cCRT + durvalumab
Intratumoral study
Intratumoral study
Advanced NSCLC
86974680NSC1001
Phase
NCT06116786
Compound
JNJ-86974680 (A2a receptor antagonist) + cetrelimab (anti–PD-1 mAb) ± RT
Advanced or metastatic solid tumors/metastatic NSCLC
87704916LUC1001
Phase
NCT06311578
Compound
JNJ-87704916 (oncolytic virus) ± cetrelimab (anti–PD-1 mAb)
Intratumoral study
Intratumoral study
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
*Soon to be recruiting.
Ab, antibody; cCRT, concurrent chemoradiation therapy; EGFR, epidermal growth factor receptor; mAb, monoclonal antibody; CT, chemotherapy; MET, mesenchymal epithelial transition factor; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; RT, radiation therapy; SOC, standard of care; TKI, tyrosine kinase inhibitor.